We Work For Health is tracking every new U.S. biopharma facility announcement and news report, revealing more than $425 billion being invested to drive new R&D, expand manufacturing and create jobs nationwide. The continually updated database is accessible below through a state map of announcements that mention specific cities or states and also a tracker of every public commitment since January 2025.Continue reading
Category Archives: Advocacy and Regulations
Amgen Makes Repatha® Available Through AMGENNOW, A Direct-to-Patient Program in the U.S.
Eligible Patients Can Access Repatha at Nearly 60% Discount From the List Price
THOUSAND OAKS, Calif. Oct. 6, 2025 /PRNewswire/ — Amgen (NASDAQ: AMGN) today announced the launch of AmgenNow, a new direct-to-patient program starting with Repatha® (evolocumab). This follows landmark results demonstrating Repatha significantly reduced the risk of major adverse cardiovascular events (MACE) in individuals without a prior history of heart attack or stroke in the VESALIUS-CV Phase 3 trial.Continue reading
FDA Announces New ANDA Prioritization Pilot to Support U.S. Generic Drug Manufacturing and Testing
[10/3/2025] Today, the U.S. Food and Drug Administration (FDA) is announcing a new pilot prioritization program for the review of abbreviated new drug applications (ANDAs) (ANDAs) that aims to spur and reward investment in U.S. drug manufacturing and research and development and strengthen the domestic pharmaceutical supply chain by providing faster reviews for generic companies who test and manufacture their products in the U.S.Continue reading
Administration Announces a 100 Percent Potential Tariff on Branded or Patented Pharmaceuticals
President Trump posted the following on Truth Social on Thursday, September 25, 2025: “Starting October 1st, 2025, we will be imposing a 100% Tariff on any branded or patented Pharmaceutical Product, unless a Company IS BUILDING their Pharmaceutical Manufacturing Plant in America. “IS BUILDING” will be defined as, “breaking ground” and/or “under construction.” There will, therefore, be no Tariff on these Pharmaceutical Products if construction has started. Thank you for your attention to this matter!” Source: https://truthsocial.com/@realDonaldTrump/115267512131958759Continue reading
Next up for Section 232 Investigations – Medtech
The US Commerce Department disclosed on September 24, 2025 that new “Section 232” investigations into the import of personal protective equipment, medical items, robotics and industrial machinery were opened on September 2, 2025 but not previously disclosed.Continue reading
AdvaMed, Patient Groups, State Medtech Associations Urge Medicare Coverage of Breakthrough Medtech
In a letter to CMS Administrator Dr. Mehmet Oz, the 67 organizations noted medtech enables remarkable patient outcomes, yet FDA-designated, authorized breakthrough medtech faces years of delays in Medicare coverage. Continue reading
Governor Katie Hobbs Takes Action to Lower Cost of Prescription Drugs for Arizonans
New initiative will help Arizonans save up to 80% on qualifying medications
Stanford faculty member George Tidmarsh, M.D., Ph.D. named Director of Center for Drug Evaluation and Research
The U.S. Food and Drug Administration today announced the appointment of George Francis Tidmarsh, M.D., Ph.D., as Director of the Center for Drug Evaluation and Research (CDER). In this role, Dr. Tidmarsh will lead the FDA’s efforts to ensure safe, effective, and high-quality drugs are available to the American people.Continue reading
The R & D Expensing Fix in the One Big Beautiful Bill
New tax law restores immediate R&D expensing in the US
As Congress Focuses on the Budget – Life Science Leaders Focus on an EPIC solution.
From full page ads in the Boston Globe to panels of thought leaders at BIO 2025,and podcasts, leaders are highlighting the problems being created by the Pill Penalty that is part of the Inflation Reduction Act. As Congress works through the Budget Reconciliation Process, the EPIC Act could be a solution.Continue reading